Skip to main content

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Trial Status: Closed to Accrual

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

Inclusion Criteria

  • Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.
  • Presence of measurable tumor
  • Able to swallow medication

Exclusion Criteria

  • Major surgery within 4 weeks before randomization
  • Last dose of prior chemotherapy received less than 4 weeks prior to randomization
  • Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
  • Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
  • Significant cardiac events
  • Previous ZD6474 treatment

Colorado

Denver
University of Colorado
Status: COMPLETED

Florida

Jacksonville
Mayo Clinic in Florida
Status: COMPLETED

Minnesota

Rochester
Mayo Clinic in Rochester
Status: COMPLETED

Texas

Houston
M D Anderson Cancer Center
Status: COMPLETED

Trial Phase Phase III

Trial Type Treatment

Lead Organization
Genzyme

  • Primary ID D4200C00058
  • Secondary IDs NCI-2010-00997, 2005-005077-29, LPS14811
  • Clinicaltrials.gov ID NCT00410761